- Full Year 2023 HUTCHMED (China) Ltd Earnings Call TranscriptFeb 28, 2024€14.5 (+2.84%)Earnings
- HUTCHMED (China) Ltd at Deutsche Bank ADR Investor Conference (Virtual) TranscriptNov 09, 2023
- Half Year 2023 HUTCHMED (China) Ltd Earnings Call TranscriptJul 31, 2023€13.5 (+6.30%)Earnings
- HUTCHMED (China) Ltd at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- HUTCHMED (China) Ltd at Jefferies Healthcare Conference TranscriptJun 08, 2023
- HUTCHMED (China) Ltd at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Full Year 2022 HUTCHMED (China) Ltd Earnings Call TranscriptFeb 28, 2023Earnings
- HUTCHMED (China) Ltd Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China Call TranscriptJan 23, 2023
- HUTCHMED (China) Ltd at OTC Markets and Deutsche Bank dbVIC ADR Virtual Investor Conference TranscriptNov 17, 2022
- HUTCHMED (China) Ltd at Bank of America Precision Oncology Conference TranscriptOct 03, 2022
- HUTCHMED (China) Ltd FRESCO-2 Data at ESMO Call TranscriptSep 12, 2022
- Half Year 2022 HUTCHMED (China) Ltd Earnings Call TranscriptAug 01, 2022€12.5 (+2.46%)Earnings
- HUTCHMED (China) Ltd Company Update: Surufatinib FDA NDA Status Corporate Call TranscriptMay 02, 2022
- Full Year 2021 HUTCHMED (China) Ltd Earnings Call TranscriptMar 03, 2022€23.4 (-5.65%)Earnings
- HUTCHMED (China) Ltd at OTC Markets and Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptNov 17, 2021
- HUTCHMED (China) Ltd and Epizyme Inc Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® in Greater China Call TranscriptAug 09, 2021
- Half Year 2021 HUTCHMED (China) Ltd Earnings Call TranscriptJul 28, 2021€30.6 (-2.55%)Earnings
- HUTCHMED (China) Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- HUTCHMED (China) Ltd Corporate Call TranscriptMay 27, 2021
- HUTCHMED (China) Ltd virtual investor update Call TranscriptMay 26, 2021
- HUTCHMED (China) Ltd at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 11, 2021
- Full Year 2020 Hutchison China MediTech Ltd Earnings Call TranscriptMar 04, 2021€24Earnings
- Hutchison China MediTech Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Half Year 2020 Hutchison China MediTech Ltd Earnings Call TranscriptJul 30, 2020€22.8 (+3.64%)Earnings
- Hutchison China MediTech Ltd Investor Update at ASCO TranscriptJun 01, 2020
- Hutchison China MediTech Ltd at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Hutchison China MediTech Ltd at PR Newswire and BetterInvesting (NAIC) Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptMar 19, 2020
- Full Year 2019 Hutchison China MediTech Ltd Earnings Call TranscriptMar 03, 2020€21.6 (+5.88%)Earnings
- Hutchison China MediTech Ltd at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Hutchison China MediTech Ltd at Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptNov 13, 2019
- Hutchison China MediTech Limited - Special Call TranscriptSep 30, 2019
- Hutchison China MediTech Ltd at Morgan Stanley Healthcare Conference TranscriptSep 11, 2019
- Half Year 2019 Hutchison China MediTech Ltd Earnings Presentation TranscriptJul 30, 2019
- Hutchison China MediTech Ltd at Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptMay 15, 2019
- Full Year 2018 Hutchison China MediTech Ltd Earnings Call TranscriptMar 11, 2019Earnings
- Full Year 2018 Hutchison China MediTech Ltd Earnings Call TranscriptMar 11, 2019Earnings
HUTCHMED (China) Ltd at Bank of America Global Healthcare Conference Transcript
Hey, everyone. Good afternoon, and welcome to day 2 of the 2023 BofA Healthcare Conference. Thanks for joining the session with HUTCHMED. My name is Alec Stranahan. I'm Vice President and senior biotech analyst covering HUTCHMED here at BofA. And I'm pleased to be joined by Mark -- Mike, who's the CMO of HUTCHMED. And I think Mike's going to give some prepared remarks to set the stage, and then we'll jump into Q&A. So over to you Mike.
()- -
Yes. Thank you, Alec. Yes, it's a great pleasure to be here. And I just want to have a few words about HUTCHMED, is a biotech company based -- headquartered in Hong Kong. It's been for 20 years, and we have three products already marketed in China, savolitinib, fruquintinib and surufatinib. And we also have a full integrated discovery, development and the commercial pipeline in China. In -- extra China side,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)